BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37657032)

  • 1. Analysis of genomic alterations in primary central nervous system lymphoma.
    He X; Fan X; Shan Y; Ji X; Su L; Wang Y
    Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
    Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
    Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.
    Balikov DA; Hu K; Liu CJ; Betz BL; Chinnaiyan AM; Devisetty LV; Venneti S; Tomlins SA; Cani AK; Rao RC
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.
    Barakat M; Albitar M; Whitney R; Abdulhaq H
    Cancer Treat Res Commun; 2021; 27():100310. PubMed ID: 33581493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
    Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
    World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
    Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
    J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
    Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
    Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of primary central nervous system lymphoma.
    Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
    Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
    Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
    Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Zhu Q; Wang J; Zhang W; Zhu W; Wu Z; Chen Y; Chen M; Zheng L; Tang J; Zhang S; Wang D; Wang X; Chen G
    Front Genet; 2022; 13():878618. PubMed ID: 35646048
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
    Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.